Post hoc analysis of 3 phase 3 aflibercept trials in macular oedema after retinal vein occlusion: in COPERNICUS (113 patients), starting <1 vs >3 months after diagnosis gave week-24 vision gains of 19.8 vs 11.9 letters; findings were similar in GALILEO and VIBRANT.
Secondary analysis
Sharma et al. Effects of Time from Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase III Trials